Evidence of CNS activity of antibody-based therapeutics for relapsed/refractory B-ALL
| Agent . | Mechanism of action . | Evidence of CNS activity∗ . |
|---|---|---|
| Blinatumomab | CD3-CD19 bispecific T-cell engager | Limited: 1 retrospective series84 |
| Inotuzumab ozogamicin | CD22 antibody-drug conjugate | None |
| Tisagenlecleucel | CD19 CAR T cells | Moderate: pooled post hoc analysis of prospective studies and multiple retrospective series85-87 |
| Brexucabtagene autoleucel | CD19 CAR T cells | Limited: extrapolated from experience with other CAR T-cell therapies |
| Agent . | Mechanism of action . | Evidence of CNS activity∗ . |
|---|---|---|
| Blinatumomab | CD3-CD19 bispecific T-cell engager | Limited: 1 retrospective series84 |
| Inotuzumab ozogamicin | CD22 antibody-drug conjugate | None |
| Tisagenlecleucel | CD19 CAR T cells | Moderate: pooled post hoc analysis of prospective studies and multiple retrospective series85-87 |
| Brexucabtagene autoleucel | CD19 CAR T cells | Limited: extrapolated from experience with other CAR T-cell therapies |
Please see text and references cited for additional details.